Nextage Therapeutics
A pioneer in targeted nano-liposomes based drug delivery across the Blood-Brain-Barrier
Company Overview
Snapshot
Founded in March 2006, Nextage Therapeutics operates with 11–50 employees and became public on TASE in August 2020. In March 2026, the company secured a European patent for its breakthrough nano-liposome platform.
Business overview
Nextage Therapeutics specializes in targeted nano-liposome-based drug delivery across the blood-brain barrier. The company has developed a proprietary BTLs drug delivery platform, currently being studied for various therapeutic applications, with its lead drug candidate targeting glioblastoma. Through its subsidiary, Nextar Chempharma Solutions, it also provides development and commercial manufacturing services for pharmaceuticals and medical devices, covering drug substance synthesis, formulation development, scale-up, and sterile manufacturing. The company operates within the Health Tech & Life Sciences sector, focusing on drug delivery and discovery.
Strategic signal
In March 2026, Nextage Therapeutics secured a European patent for its nano-liposome platform, signaling significant intellectual property validation and potential for broader market access and commercialization within the European pharmaceutical landscape. This development underscores the company's commitment to innovation in drug delivery and strengthens its position in the competitive health tech and life sciences sector.
Log in to access full profile ›Company Intelligence Q&A
- When did Nextage Therapeutics go public?
- Nextage Therapeutics became public on TASE in August 2020.
- What was a key strategic move for Nextage Therapeutics in March 2025?
- In March 2025, Nextage Therapeutics completed a merger with Nextar Chempharma Solutions.
- What significant intellectual property milestone did Nextage Therapeutics achieve in March 2026?
- In March 2026, Nextage Therapeutics secured a European patent for its breakthrough nano-liposome platform.
- Who was appointed CEO of Nextage Therapeutics in February 2026?
- In February 2026, Ilan Avni was appointed as the CEO of Nextage Therapeutics.
- What collaboration did Nextage Therapeutics announce in May 2021?
- In May 2021, MindMed announced the launch of a collaboration with Nextage Therapeutics' Brain Targeting Liposome System.